18F-FDG PET/CT与增强CT评估食管鳞癌新辅助免疫化疗后淋巴结状态
该回顾性研究纳入161例接受新辅助免疫化疗后行食管切除术的食管鳞癌患者,评估18F-FDG PET/CT与增强CT对残留转移淋巴结的诊断效能。结果显示PET/CT参数TLG与增强CT参数短轴直径诊断效能无显著差异,但两者联合模型显著优于单独增强CT,且不同淋巴结区域的最佳预测参数和阈值不同。
要点
- PET/CT联合增强CT参数诊断淋巴结的AUC显著优于单独增强CT。
- TLG在食管旁和腹部区域诊断效能最佳。
- 淋巴结与肝脏血池SUVmax比值在喉返神经和隆突下区域诊断效能最佳。
核心结论
- 在新辅助免疫化疗后的食管鳞癌患者中,18F-FDG PET/CT评估淋巴结状态优于增强CT。
- 最佳预测参数和阈值因淋巴结区域而异,提示需区域特异性诊断标准。
研究设计与样本
- 回顾性研究分析161例接受新辅助免疫化疗后行食管切除术的食管鳞癌患者。
- 所有患者术前行18F-FDG PET/CT,其中137例同时接受增强CT。
- 以病理证实的转移与非转移淋巴结为参考,按日本食管学会分期系统评估。
主要发现
- 整体淋巴结分析中,PET最佳参数TLG与增强CT最佳参数短轴直径的AUC分别为0.830和0.797,差异无统计学意义(P=0.08)。
- TLG与短轴直径联合模型的AUC为0.863,显著优于单独短轴直径的0.797(P<0.001)。
- 亚区域分析中,TLG在食管旁组和腹部区域AUC分别为0.824和0.857。
- 淋巴结与肝脏血池SUVmax比值在喉返神经组和隆突下区域AUC分别为0.885和0.884。
关键数值与推荐
- 整体淋巴结诊断:TLG的AUC为0.830,短轴直径的AUC为0.797。
- 联合模型(TLG+短轴直径)的AUC为0.863。
- 食管旁组TLG的AUC为0.824,腹部区域TLG的AUC为0.857。
- 喉返神经组LLR的AUC为0.885,隆突下区域LLR的AUC为0.884。
临床怎么用
- 对于新辅助免疫化疗后的食管鳞癌患者,可优先采用18F-FDG PET/CT评估淋巴结状态。
- 解读淋巴结时需结合所在区域选择相应最佳参数,如食管旁和腹部区域关注TLG,喉返神经和隆突下区域关注LLR。
- 联合TLG与短轴直径可提高整体淋巴结诊断效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the detectability of residual tumor-involved lymph nodes (LNs) using 18F-FDG PET/CT and contrast-enhanced CT (CECT) parameters in patients with esophageal squamous cell carcinoma (ESCC) following neoadjuvant immunochemotherapy (NICT). METHODS: This retrospective study analyzed 161 ESCC patients who received esophagectomy following NICT. All patients underwent preoperative 18F-FDG PET/CT, and 137 also received CECT. Metastatic and nonmetastatic LNs, confirmed pathologically, were evaluated according to the Japanese Esophageal Society (JES) staging system. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curve analysis and logistic regression was used to integrate metrics for the prediction of LNs status. RESULTS: For overall lymph node analysis, there was no significant difference in diagnostic performance between the optimal PET parameter, total lesion glycolysis (TLG), and the best CECT parameter, short-axis diameter (SAD) (AUC: 0.830 vs. 0.797, P = 0.08). Nevertheless, a combined model incorporating TLG and SAD of PET/CT demonstrated significantly superior diagnostic performance compared to SAD of CECT (AUC: 0.863 vs. 0.797, P < 0.001). In subregional analyses, TLG performed best in the paraesophageal group and abdominal area, with AUCs of 0.824 and 0.857. The SUVmax ratio of lymph nodes to liver blood pool (LLR) demonstrated the highest diagnostic performance in the recurrent nerve group and subcarinal area, with AUCs of 0.885 and 0.884, respectively. CONCLUSION: 18F-FDG PET/CT is superior to CECT in assessing LNs status in ESCC patients after NICT. The optimal predictive parameters and thresholds vary across LN regions, underscoring the importance of region-specific diagnostic criteria.
引用
- Wang Y, Hu X, Yang T, et al. 18F-FDG PET/CT and contrast-enhanced CT evaluation of lymph node status after neoadjuvant immunochemotherapy in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2025. PMID: 41091187. doi:10.1007/s00259-025-07603-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。